Ranibizumab Treatment for Retinal Vein Occlusion

    Not Recruiting
  • participants needed
  • sponsor
    Kyoto University, Graduate School of Medicine
Updated on 21 January 2021
Nagahisa Yoshimura, MD, PhD
Primary Contact
Department of Ophthalmology, Kyoto University Hospital (1.4 mi away) Contact


In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Condition Macular Edema Due to BRVO/CRVO
Treatment Ranibizumab, 0.5mg, Intravitreal
Clinical Study IdentifierNCT01968616
SponsorKyoto University, Graduate School of Medicine
Last Modified on21 January 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note